Recently, KRAS testing in advanced-stage NSCLC patients has acquired a novel predictive significance, the KRAS G12C mutation being target of different small molecules currently being tested in clinical trials involving patients with advanced NSCLC in whom the actionable mutation is assessed in archived tumor tissues [8]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.